VAM
PTCT icon

Visium Asset Management’s PTC Therapeutics PTCT Stock Holding History

Visium Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-252
Closed -$12K – 1134
2015
Q2 		$12K Buy
+252
New +$14.7K ﹤0.01% 1101

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's PTCT Position: Q2 2016 in Review

Visium Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2016, closing a stake of 204,554 shares — an estimated $1.32M sold.

Visium Asset Management first reported a position in PTCT in Q3 2013 and held it in 4 quarters. The position peaked at $1.32M in Q1 2016. 118 funds tracked by Wall St. Rank hold PTCT as of Q2 2016.

  • Visium Asset Management reported no remaining PTC Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 204,554 PTC Therapeutics shares in Q2 2016, an estimated $1.32M.
  • Visium Asset Management first reported a position in PTC Therapeutics in Q3 2013 and held it in 4 quarters.
  • Visium Asset Management's PTC Therapeutics position peaked at $1.32M in Q1 2016.
  • 118 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.